CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Sitaxsentan sodium

Last Updated: May 5, 2008
Result type: Reports
Project Number: SR0132-000
Product Line: Reimbursement Review

Generic Name: Sitaxsentan sodium

Brand Name: Thelin

Manufacturer: Encysive Canada Inc.

Therapeutic Area: Pulmonary arterial hypertension (WHO class II and III)

Indications: Pulmonary arterial hypertension (WHO class II and III)

Submission Type: Resubmission

Project Status: Complete

Date Recommendation Issued: January 28, 2009

Recommendation Type: Do not list